{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-113763","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2026-10-05T21:00:54+00:00","discovered_at":"2026-10-05T21:02:00.227508+00:00","generated_at":"2026-10-12T14:57:11.980048+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Iovance raises FY2026 revenue guidance to $410M–$420M, ~15% above prior range at midpoint","bullets":["FY2026 revenue guidance raised to $410M–$420M; midpoint is $55M (~15%) above prior $350M–$370M range.","2Q26 revenue exceeded guidance by more than 10%; ~$304M cash as of June 30, 2026 supports runway into 2H28.","~100 authorized treatment centers as of Oct 5, 2026; ~2,000 patients treated with commercial and clinical Iovance TIL products.","5-year Amtagvi data: 31.4% ORR, 19.7% OS, mDOR 36.5 months; real-world ORR ~44% and 52% in patients with ≤2 prior lines.","TILVANCE-301 Phase 3 frontline melanoma trial (N=670, 80+ sites) enrolls on track; IOV-LUN-202 NSCLC showed 25.6% ORR."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-113763","json":"https://secwatch.observer/filing/0001104659-26-113763.json","markdown":"https://secwatch.observer/filing/0001104659-26-113763.md","text":"https://secwatch.observer/filing/0001104659-26-113763.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465926113763/0001104659-26-113763-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465926113763/tm2627047d1_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T14:57:11.980048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}